Mechanisms of abdominal aortic aneurysm formation

Abdominal aortic aneurysms (AAA) are permanent dilations in the infra-renal area in which the arterial tissue is characterized by inflammation and medial degeneration. AAAs are a common vascular disorder and cause significant mortality in the aged population. Despite the high prevalence of this disease, there is limited knowledge on the mechanisms responsible for the vascular pathology. Therefore, current therapeutic options are restricted to surgical intervention and are predicated on the assumed propensity for rupture as the vessel enlarges. Current research focuses on inflammatory processes and their role in proteolytic degradation of the elastin and collagen fibers of the vessel wall. Definition of specific mechanisms would identify target sites for potential pharmacologic intervention and markedly improve the medical treatment and prognosis of AAA.

[1]  Mark D. Huffman,et al.  Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. , 2000, Surgery.

[2]  M. Jeune,et al.  Effect of Matrix Metalloproteinase Inhibition on Progression of Atherosclerosis and Aneurysm in LDL Receptor‐Deficient Mice Overexpressing MMP‐3, MMP‐12, and MMP‐13 and on Restenosis in Rats after Balloon Injury , 1999, Annals of the New York Academy of Sciences.

[3]  S Glagov,et al.  Aneurysmal and occlusive atherosclerosis of the human abdominal aorta. , 2001, Journal of vascular surgery.

[4]  P. Libby,et al.  Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  R. Mecham,et al.  Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. , 1995, The Journal of clinical investigation.

[6]  J. Scholes,et al.  Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. , 1993, The Journal of surgical research.

[7]  J. Powell,et al.  Interleukin-6 (IL-6) and the Prognosis of Abdominal Aortic Aneurysms , 2001, Circulation.

[8]  A Daugherty,et al.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. , 2000, The Journal of clinical investigation.

[9]  M. Halks-Miller,et al.  Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. , 2001, The American journal of pathology.

[10]  Mark D. Huffman,et al.  Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. , 1998, The Journal of clinical investigation.

[11]  A. Daugherty,et al.  Chronic Angiotensin II Infusion Promotes Atherogenesis in Low Density Lipoprotein Receptor −/− Mice , 1999, Annals of the New York Academy of Sciences.

[12]  M. Leinonen,et al.  Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[13]  H. Nagase,et al.  Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[14]  D. Loskutoff,et al.  Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. , 1995, The Journal of clinical investigation.

[15]  D Bergqvist,et al.  Literature review of surgical management of abdominal aortic aneurysm. , 2001, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[16]  M. David Tilson,et al.  Suggested standards for reporting on arterial aneurysms , 1991 .

[17]  W. Pearce,et al.  Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. , 1999, Journal of vascular surgery.

[18]  Alan Daugherty,et al.  Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease , 2002, Vascular medicine.

[19]  W. Pearce,et al.  Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. , 1993, American Journal of Pathology.

[20]  A. Okumura,et al.  Angiotensin I-converting enzyme gene polymorphism in intracranial saccular aneurysm individuals. , 1998, Neurological research.

[21]  J. Hallett,et al.  Management of abdominal aortic aneurysms. , 2000, Mayo Clinic proceedings.

[22]  D Bergqvist,et al.  Incidence and Prevalence of Abdominal Aortic Aneurysms, Estimated by Necropsy Studies and Population Screening by Ultrasound a , 1996, Annals of the New York Academy of Sciences.

[23]  M. Leinonen,et al.  Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. , 2001, Journal of vascular surgery.

[24]  W. Pearce,et al.  Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. , 1997, Journal of vascular surgery.

[25]  C. Quick,et al.  Epidemiology and potential for prevention of abdominal aortic aneurysm , 1998, The British journal of surgery.

[26]  D. Reed,et al.  Are Aortic Aneurysms Caused by Atherosclerosis? , 1992, Circulation.

[27]  Paul L Huang,et al.  Accelerated Atherosclerosis, Aortic Aneurysm Formation, and Ischemic Heart Disease in Apolipoprotein E/Endothelial Nitric Oxide Synthase Double-Knockout Mice , 2001, Circulation.

[28]  J. K. Lee,et al.  Experimental Abdominal Aortic Aneurysms in Mice Lacking Expression of Inducible Nitric Oxide Synthase , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[29]  G. Sicard,et al.  Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. , 1994, Journal of vascular surgery.

[30]  W. Pearce,et al.  Interleukin-1β and tumor necrosis factor-α release in normal and diseased human infrarenal aortas * ** * , 1992 .

[31]  M M Thompson,et al.  Arterial aneurysms , 2000, BMJ : British Medical Journal.

[32]  A. Hingorani,et al.  The effect of tumor necrosis factor binding protein and interleukin-1 receptor antagonist on the development of abdominal aortic aneurysms in a rat model. , 1998, Journal of vascular surgery.

[33]  K. Ozsvath,et al.  Expression of two novel recombinant proteins from aortic adventitia (kappafibs) sharing amino acid sequences with cytomegalovirus. , 1997, The Journal of surgical research.

[34]  J. Powell,et al.  Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[35]  A. R. Brady,et al.  Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms , 1998, The Lancet.

[36]  P. Shah,et al.  Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. , 1997, Circulation.

[37]  J D Humphrey,et al.  Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. , 2001, Journal of vascular surgery.

[38]  M. Thompson,et al.  Ubiquitous Elevation of Matrix Metalloproteinase-2 Expression in the Vasculature of Patients With Abdominal Aneurysms , 2001, Circulation.

[39]  O. Topolcan,et al.  Plasma endothelin levels in patients with abdominal aortic aneurysms. , 1999, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[40]  B. Baxter,et al.  MMP Inhibition in Abdominal Aortic Aneurysms: Rationale for a Prospective Randomized Clinical Trial , 1999, Annals of the New York Academy of Sciences.

[41]  G. Fadda,et al.  Abdominal aortic aneurysm in normotensive patients: association with angiotensin-converting enzyme gene polymorphism. , 2001, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[42]  D. Rubinsztein,et al.  The ACE I allele is associated with increased risk for ruptured intracranial aneurysms , 2000, Journal of medical genetics.

[43]  S A Wickline,et al.  Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. , 1997, The American journal of pathology.

[44]  G. Chejfec,et al.  Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. , 1992, Journal of vascular surgery.

[45]  B. Kelley,et al.  Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. , 2001, Journal of vascular surgery.

[46]  A. Daugherty,et al.  Antagonism of AT2 receptors augments Angiotensin II‐induced abdominal aortic aneurysms and atherosclerosis , 2001, British journal of pharmacology.

[47]  Jiqiu Chen,et al.  Hypertension Does Not Account for the Accelerated Atherosclerosis and Development of Aneurysms in Male Apolipoprotein E/Endothelial Nitric Oxide Synthase Double Knockout Mice , 2001, Circulation.

[48]  M. Tonelli,et al.  Content and turnover of extracellular matrix protein in human "nonspecific" and inflammatory abdominal aortic aneurysms. , 1993, European journal of vascular surgery.

[49]  W. Pearce,et al.  Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. , 1990, The American journal of pathology.

[50]  G. Sicard.  Human abdominal aortic aneurysms: Immunophenotypic analysis suggesting an immune-mediated response: Koch AE, Haines GK, Rizzo RJ, et al. Am J Pathol 1990;137:1199–2139 , 1992 .

[51]  É. Allaire,et al.  Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. , 1998, The Journal of clinical investigation.

[52]  É. Allaire,et al.  Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. , 1998, Circulation.

[53]  S. Shapiro,et al.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. , 2000, The Journal of clinical investigation.

[54]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[55]  J. K. Lee,et al.  Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. , 1999, Biochemical and biophysical research communications.

[56]  D. Carey,et al.  The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. , 1999, Journal of vascular surgery.